Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.59 |
| ▸ | FLT3 | P36888 | 7/20 | 0.59 |
| ▸ | GSK3B | P49841 | 6/20 | 0.59 |
| ▸ | IGF1R | P08069 | 4/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.59 |
| ▸ | KIT | P10721 | 4/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | FLT1 | P17948 | 4/20 | 0.59 |
| ▸ | FLT4 | P35916 | 4/20 | 0.59 |
| ▸ | TEK | Q02763 | 4/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11656533 | 0.82 | RAB9A (0.62) | KDRGSK3BPDGFRBPDGFRACDK4 | |
| SCHEMBL78989 | 0.81 | PRKD3 (0.62) | KDRFLT3AURKASMN1; SMN2NPSR1 | |
| SCHEMBL29415921 | 0.81 | PRKD3 (0.62) | KDRFLT3AURKASMN1; SMN2NPSR1 | |
| SCHEMBL31615194 | 0.80 | NPC1 (0.61) | KDRGSK3BAURKAKDM4EMAPT | |
| SCHEMBL3148480 | 0.80 | NPC1 (0.61) | KDRGSK3BAURKAKDM4EMAPT | |
| SCHEMBL4789937 | 0.80 | KDR (0.67) | KDRFLT3GSK3BIGF1RPDGFRB | |
| SCHEMBL3959789 | 0.79 | PRKD3 (0.61) | KDRFLT3AURKASMN1; SMN2NPSR1 | |
| SCHEMBL1155691 | 0.76 | KDR (0.63) | KDRFLT3GSK3BIGF1RPDGFRB | |
| SCHEMBL1155976 | 0.76 | KDR (0.63) | KDRFLT3GSK3BIGF1RPDGFRB | |
| Maleimide SCHEMBL1155440 | 0.74 | KDR (1.00) | KDRFLT3GSK3BIGF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841319-B2 | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2014-09-23 | — | — | US | disclosed |
| EP-1819697-B1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011163247-A3 | HYBRID TIME AND FREQUENCY DOMAIN CSI FEEDBACK SCHEME | QUALCOMM INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2217231-B1 | USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN LEUKEMIA MANAGEMENT | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-8008320-B2 | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors | Johannes Gutenberg-Universitatis (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20110028415-A1 | USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN LEUKENIA MANAGEMENT | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028415-A1 | USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN LEUKENIA MANAGEMENT | NPM1, INMT, MCL1 | KDR 4432/4885FLT3 381/4885GSK3B 4653/4885 |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | FLT4, KDR, FLT1 | KDR 2/4885FLT3 540/4885GSK3B 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.